Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.
Lead Product(s): AT-04
Therapeutic Area: Neurology Product Name: AT-04
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Attralus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 17, 2022
Details:
A novel approach being pioneered at Ossianix uses its patented VNAR phage display libraries to identify single domain antibodies with high affinity and specificity against the COVID-19 spike protein.
Lead Product(s): VNAR antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020